Sedana Medical AB (publ) (SEDANA.ST)
SEK 10.24
(0.2%)
SEK 10.24
(0.2%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 108.98 Million SEK | 26.61% |
| 2022 | 86.07 Million SEK | -19.34% |
| 2021 | 106.7 Million SEK | 20.03% |
| 2020 | 88.9 Million SEK | 69.62% |
| 2019 | 52.41 Million SEK | 22.19% |
| 2018 | 42.89 Million SEK | 38.59% |
| 2017 | 30.95 Million SEK | 35.01% |
| 2016 | 22.92 Million SEK | 28.45% |
| 2015 | 17.84 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 34.8 Million SEK | 12.4% |
| 2024 Q2 | 28.95 Million SEK | -16.81% |
| 2024 Q3 | 28.26 Million SEK | -2.37% |
| 2023 Q2 | 26.59 Million SEK | -3.25% |
| 2023 Q1 | 27.48 Million SEK | 6.78% |
| 2023 Q4 | 30.96 Million SEK | 29.33% |
| 2023 Q3 | 23.93 Million SEK | -9.99% |
| 2023 FY | 108.98 Million SEK | 26.61% |
| 2022 Q1 | 22.99 Million SEK | -29.89% |
| 2022 Q2 | 18.89 Million SEK | -17.81% |
| 2022 FY | 86.07 Million SEK | -19.34% |
| 2022 Q3 | 18.44 Million SEK | -2.38% |
| 2022 Q4 | 25.74 Million SEK | 39.57% |
| 2021 Q2 | 26.19 Million SEK | -8.44% |
| 2021 FY | 106.7 Million SEK | 20.03% |
| 2021 Q1 | 28.6 Million SEK | 19.37% |
| 2021 Q4 | 32.78 Million SEK | 71.49% |
| 2021 Q3 | 19.12 Million SEK | -27.0% |
| 2020 Q4 | 23.96 Million SEK | 67.66% |
| 2020 FY | 88.9 Million SEK | 69.62% |
| 2020 Q3 | 14.29 Million SEK | -47.1% |
| 2020 Q2 | 27.02 Million SEK | 14.37% |
| 2020 Q1 | 23.62 Million SEK | 61.51% |
| 2019 Q3 | 12.01 Million SEK | -10.09% |
| 2019 Q2 | 13.36 Million SEK | 7.76% |
| 2019 Q4 | 14.62 Million SEK | 21.73% |
| 2019 FY | 52.41 Million SEK | 22.19% |
| 2019 Q1 | 12.4 Million SEK | 8.2% |
| 2018 Q1 | 10.78 Million SEK | 28.62% |
| 2018 Q2 | 11.3 Million SEK | 4.78% |
| 2018 Q3 | 9.33 Million SEK | -17.38% |
| 2018 Q4 | 11.46 Million SEK | 22.74% |
| 2018 FY | 42.89 Million SEK | 38.59% |
| 2017 Q2 | 8.09 Million SEK | 13.4% |
| 2017 Q3 | 7.32 Million SEK | -9.58% |
| 2017 Q4 | 8.38 Million SEK | 14.55% |
| 2017 Q1 | 7.14 Million SEK | -9.68% |
| 2017 FY | 30.95 Million SEK | 35.01% |
| 2016 Q1 | 5.86 Million SEK | 0.0% |
| 2016 FY | 22.92 Million SEK | 28.45% |
| 2016 Q4 | 7.9 Million SEK | 47.54% |
| 2016 Q2 | 3.79 Million SEK | -35.4% |
| 2016 Q3 | 5.35 Million SEK | 41.37% |
| 2015 FY | 17.84 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -1957.41% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 63.746% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 63.746% |
| Arcoma AB | 11.07 Million SEK | -884.383% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 22.146% |
| BICO Group AB (publ) | 1.83 Billion SEK | 94.047% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 56.358% |
| CellaVision AB (publ) | 463.04 Million SEK | 76.464% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -3536.336% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 483.546% |
| C-Rad AB (publ) | 66.01 Million SEK | -65.085% |
| Duearity AB (publ) | -4.17 Million SEK | 2708.449% |
| Dignitana AB (publ) | 58.97 Million SEK | -84.804% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 360.72% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.189% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 317.019% |
| Iconovo AB (publ) | 17.57 Million SEK | -519.997% |
| Integrum AB (publ) | 690.56 Thousand SEK | -15681.494% |
| Luxbright AB (publ) | -2.79 Million SEK | 3996.526% |
| Mentice AB (publ) | 236.38 Million SEK | 53.896% |
| OssDsign AB (publ) | 83.64 Million SEK | -30.29% |
| Paxman AB (publ) | 12.61 Million SEK | -763.695% |
| Promimic AB (publ) | 38.51 Million SEK | -182.957% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 314.728% |
| SciBase Holding AB (publ) | 16.03 Million SEK | -579.56% |
| ScandiDos AB (publ) | 47.55 Million SEK | -129.168% |
| Sectra AB (publ) | 557.55 Million SEK | 80.454% |
| Senzime AB (publ) | 8.33 Million SEK | -1206.883% |
| SpectraCure AB (publ) | -9.22 Million SEK | 1281.622% |
| Stille AB | 132.17 Million SEK | 17.545% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 94.49% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 73.86% |